ArticleImmunity, inflammation and disease2026
Ginsenoside Rg3 Ameliorates Psoriasis-Like Dermatitis through Inhibition of NF-κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on the mechanisms of Panax ginseng and its active components in maintaining skin homeostasis and disease intervention.Chinese medicine · 2026Review
- Ginsenoside Rg3 Ameliorates Psoriasis-Like Dermatitis through Inhibition of NF-κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPsoriasis, characterized as a persistent cutaneous inflammatory condition driven by aberrant immunity, exhibits pathogenesis and disease course heavily influenced by sustained inflammatory activity. Ginsenoside Rg3 (Grg3), a traditional Chinese medicinal compound, has shown notable therapeutic effects on various inflammatory diseases. However, its therapeutic efficacy and mechanisms of action in the treatment of psoriasis remain unclear.
methodIn this study, we utilized 6 to 8-week-old female BALB/c mice and applied 5% imiquimod (IMQ) cream to their dorsal skin to establish a psoriasis-like dermatitis model. Twenty-five mice were randomly divided into five groups: control, model, and the Grg3-L/M/H groups, receiving dosages of 5, 10, and 20 mg/kg/day, respectively, with three mice in each group. Grg3 was administered continuously for 7 days to evaluate its effects on the skin of the psoriasis mice. The following methodologies were employed: the Psoriasis Area and Severity Index) for clinical severity scoring, hematoxylin-eosin staining for histomorphological analysis, alongside immunohistochemistry, immunofluorescence, and flow cytometry for detailed protein and cellular profiling to assess the expression levels of the keratinocyte proliferation marker Ki-67, inflammatory cytokines, NLRP3 inflammasome-related factors, and NF-κB pathway-related proteins in vivo.
resultSignificant reductions in PASI scores were observed in IMQ-treated BALB/c murine models of psoriasis following Grg3 treatment. It decreases epidermal thickness, inhibits the proliferation and differentiation of epidermal cells, and reduces the expression of the inflammatory cytokine interleukin-17 (IL-17) in splenic lymphocytes. Additionally, an increase in Foxp3 + CD4+ regulatory T cell (Treg) proportion and a decrease in the expression levels of NLRP3, apoptosis-associated speck-like protein (ASC), caspase-1, and IL-1β were observed following Grg3 administration. Furthermore, A concomitant downregulation of p-p65 expression and its downstream effectors, such as the pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), was also observed.
conclusionOur findings indicate that Grg3 confers protective effects in a murine model of imiquimod-induced psoriasis-like dermatitis. The potential therapeutic properties of Grg3 potentially involve modulation of NLRP3 inflammasome activation, suppression of NF-κB signaling, and restoration of Th17/Treg cell homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.